GW Pharmaceuticals plc (“GW”) and Bayer Healthcare AG (“Bayer”) announce that they have extended their marketing agreement for Sativex®, GW’s cannabis-based medicinal extract product, to the Canadian ... more
GW is pleased to announce that it is raising approximately £20 million before expenses through a placing for cash of 9,904,395 new GW ordinary shares at 200 pence per share.... more
GW Pharmaceuticals plc (“GW”) and Bayer AG (“Bayer”) have entered into an exclusive marketing agreement for GW’s cannabis-based medicinal extract product, to be marketed under the Sativex® brand name.... more
GW announces the appointment of Hans Schram as a non-executive director with immediate effect. Mr Schram has over 20 years experience in global pharmaceutical business development and marketing.... more
GW Pharmaceuticals plc, the company developing a portfolio of non-smoked cannabis-based prescription medicines, announces that Professor Roger Pertwee, Professor of Neuropharmacology at the University... more
GW announces that the regulatory dossier for the Company’s first cannabis-based prescription medicine has been submitted to the UK Medicines Control Agency as planned.... more
GW notes recent media comments relating to its commercialisation discussions. The Company has consistently stated its commercial strategy to be to enter into partnerships following Phase III trial res... more
GW Pharmaceuticals plc, the company developing a portfolio of non-smoked, cannabis-based prescription medicines, has established an extensive research collaboration with Professor Raphael Mechoulam, f... more
GW Pharmaceuticals plc, the company licensed by the UK Home Office to work with cannabis and a range of controlled drugs for medical research purposes, announces its preliminary results for the year e... more
